TORONTO, Oct. 29 /CNW/ - Dalton Medicinal Chemistry Partners, the
Medicinal Chemistry arm of Dalton Pharma Services, announces that it has
achieved a targeted milestone in its Medicinal Chemistry agreement with
Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment
of an undisclosed amount.
Dalton Medicinal Chemistry Partners is utilizing their medicinal
chemistry expertise to design and synthesize novel compounds against an
antiviral target selected by Boehringer Ingelheim (Canada) Ltd. Peter Pekos,
President of Dalton Pharma Services, said: "We are pleased to achieve this
milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd.
It is a pleasure working with the talented team at BI."
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health
Canada approved contract pharmaceutical manufacturer that supplies chemistry
and analytical services to the biotechnology and pharmaceutical industries in
the areas of chemistry, medicinal chemistry and fine chemical manufacture.
Dalton provides cGMP manufacturing and sterile filling services to its
customers at any stage of the regulatory process (Phase I, II, III or
commercial). In its state of the art cGMP facilities, Dalton produces active
pharmaceutical ingredients (API) at the gram or kilogram scale. Dalton carries
out sterile fills to produce batches of finished drug product in vials or
syringes, either aseptically filled or terminally sterilized, under fully
validated conditions. In addition, Dalton's analytical chemistry laboratory
offers method development, validation and ICH stability programs to its
For further information:
For further information: Peter Pekos, President & CEO, Dalton Pharma
Services, 349 Wildcat Road, Toronto, Ontario, email@example.com, Tel: (416)
661-2102, Fax: (416) 661-2108